Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens

Table 3 Patient characteristics in the training set (n = 283), n (%)

Characteristics	Sensitive group (n = 36)	Resistant group (n = 247)	P value
Sex
Male	20 (55.56)	141 (57.09)	0.863
Female	16 (44.44)	106 (42.91)
Age, years
mean ± SD	63.44 ± 8.71	59.33 ± 10.96	0.032a
Histology
Adenocarcinoma	53 (100.00)	352 (100.00)	-
Sampling location
Colon	20 (55.56)	169 (68.42)	0.126
Rectum	16 (44.44)	78 (31.58)
Stage
II	13 (36.11)	85 (34.41)	0.841
III	23 (63.89)	162 (65.59)

^aP < 0.05.